PDF
(Download)
|
- Devil's Claw (Harpagophytum procumbens)
- Harpagoside
|
Date:
10-15-2013 | HC# 061342-482
|
Re: New Knowledge of Harpagoside: Distribution, Biosynthesis/Accumulation, and Pharmacology
Georgiev MI, Ivanovska N, Alipieva K,
Dimitrova P, Verpoorte R. Harpagoside: from Kalahari Desert to pharmacy shelf. Phytochemistry. August 2013;92:8-15.
Devil's claw (Harpagophytum procumbens and H.
zeyheri) species have been used traditionally by the Khoisan people of
Africa for fever, digestive problems, diabetes, hypertension, and blood
diseases. Early studies found tuber extracts effective in rheumatoid arthritis,
osteoarthritis, tendonitis, kidney inflammation, and heart disease. The
European Pharmacopoeia (EP) lists devil's claw for rheumatic and arthritic
issues.
Devil's claw grows slowly and has limited
distribution. An iridoid glycoside, harpagoside, isolated in 1962, is considered
the main component of devil's claw's iridoid pool and main active compound.
Iridoids are found widely in plants. Harpagoside occurs in underground and
aboveground parts of plants in several families and genera, in widely varying
amounts. A metabolomics study found that two of five mullein (Verbascum spp.) species accumulate
potentially commercial amounts of harpagoside in leaves, with a leaf metabolome
quite different from non- or lower-harpagoside-containing species.
Several ways to produce devil's claw and/or
harpagoside products sustainably are discussed. Root callus cultures have been
tried but did not produce harpagoside, a secondary metabolite. Hairy root
cultures have produced clones that can grow while submerged and accumulate 0.32
mg harpagoside/g dry root mass. While less than whole plants, this illustrates
the feasibility of biotechnological production. Better selection of strains and
knowledge of pathways involved are needed. Other researchers report a two-step
method to propagate devil's claw in vitro. Tubers were comparable to wild
plants in harpagoside and harpagide (another iridoid glycoside) content.
High-speed countercurrent chromatography
(HSCCC) efficiently separates harpagoside from plant extracts, producing, for
example, highly purified harpagoside from scrophularia (Scrophularia ningpoensis) roots. Harpagoside research has
stimulated new analytical methods using high-performance liquid chromatography
(HPLC). HPLC analysis of devil's claw tinctures reveals that its iridoids are
stable, with levels falling by less than 10% during six months of storage under
controlled conditions.
Harpagoside's biosynthetic pathways are not fully
elucidated, although early steps are known. Based on iridoid synthesis in Madagascar
periwinkle (Catharanthus roseus), hypothetical
pathways are proposed, but researchers have not yet produced higher levels of
harpagoside in cultures. No methods have been reported for artificial
synthesis.
Effects of Harpagophytum extracts are well studied
in vivo. Many studies have found that extracts are anti-inflammatory and
analgesic in edema and inflammation induced by various agents; some report
insignificant effects. This may be due to differences in extract composition. Pure
harpagoside significantly reduced or inhibited paw swelling when given orally
or intraperitoneally. Devil's claw's other active compounds include harpagide,
8-Ο-p-coumaroyl harpagide, and the phenylethanoid glycoside verbascoside.
Harpagoside content is used to standardize extracts and should equal 1.2% of
therapeutic products according to the EP. A review of 15 studies on Harpagophytum extracts concluded that at
least 50 mg/d is needed in arthritis, providing pain relief to 60% of patients.
Doloteffin, a standardized devil's claw product providing 60 mg/d harpagoside, was
reported effective in knee osteoarthritis in trials up to 54 weeks.
In vitro, a devil's
claw fraction with 88.8% harpagoside moderately inhibited nitric oxide (NO), cyclooxygenase
(COX)-1, and COX-2 in human blood. At 27.0% and 8.9%, but not at 2.0%, extracts
and pure harpagoside inhibited inducible NO synthase (iNOS) in vitro. Aqueous
extracts inhibited NO, COX-1, COX-2, and iNOS in a fibroblast cell line.
Extracts with up to 30.0% harpagoside completely inhibited 5-lipoxygenase (5-LOX).
Harpagoside suppresses lipopolysaccharide (LPS)-induced COX-2 and iNOS
expression induced in RAW 264.7 cells via the nuclear factor-kappa B (NF-κB)
signaling pathway. Findings suggest that harpagoside can disrupt the
arachidonic acid pathway. Interestingly, harpagide has COX-2-mediated
pro-inflammatory effects and can antagonize harpagoside's effects. Both
moderating and synergistic effects seem to occur among devil's claw's
compounds.
Devil's claw extracts
affect inflammatory cytokines in vitro and in vivo. A standardized Harpagophytum extract, WS 1531 (Dr.
Willmar Schwabe GmbH & Co. KG; Karlsruhe, Germany), reduced ionophone-stimulated
cysteine-leukotriene (Cys-LT) in blood and plasma from healthy volunteers more
than harpagoside or harpagoside-free fractions. Harpagophytum fractions influence transcriptional level events,
inhibiting extracellular signal-regulated protein kinase (ERK), c-Fos expression,
and DNA binding of activator protein-1 (AP-1) and cyclic adenosine
monophosphate (cAMP) response element-binding protein (CREB). Harpagoside and
standardized extracts protect against aconitine-induced arrhythmia and reperfusion-induced
ventricular arrhythmia. Harpagoside inhibited the inflammatory mediator
Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES) in human
epithelial cells, showing potential benefits in respiratory disorders. In vivo,
it reduced dopaminergic neurodegeneration and movement disorder in a
Parkinson's disease model, boosting glial cell line-derived neurotrophic
factor.
A number of possible
anti-inflammatory mechanisms are proposed. Systems biology studies are needed
to correlate pharmacological effects with active and synergistic agents in
standardized extracts of harpagoside-bearing plants and/or cultures.
—Mariann Garner-Wizard
|